Kyverna Therapeutics, Inc. Common Stock
KYTXStock
$7.44+80.66%52W
Market Cap$482.71M
P/E—
Div yield—
Beta1.73
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.68%
Price vs S&P 500 (4W)-2.18%
VGM Score47.83
Market Capitalization$482.71M
Earnings Surprise History
Q1 26-0.66est. -0.77
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KYTXKyverna Therapeutics, Inc. Common Stock | — | — | C | $7.44 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. Its pipeline includes KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version designed for multiple autoimmune indications.